Simulations Plus, Inc. has announced the release of DILIsym® 11, the latest version of its quantitative systems toxicology $(QST.AU)$ software platform, aimed at predicting drug-induced liver injury (DILI). This version introduces new features including pediatric representation, allowing for improved predictions of liver safety in children. Additionally, it offers a new T-cell model to enhance understanding of CD8+ T-cell mediated hepatocellular injury, as well as improved modeling of bile acid and cholestatic liver injury, and updated antioxidant adaptation mechanisms. This advancement is expected to aid in developing safer and more effective therapies, particularly for vulnerable pediatric populations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.